ARPC1B and nonpapillary renal cell carcinoma: Therapeutic targeting of ARPC1B in ccRCC is mechanistically supported by preclinical evidence from glioblastoma, where its modulation enhances radiotherapy sensitivity and synergizes with immune checkpoint inhibitors to augment antitumor immunity [40,44].